To Assess the Efficacy and Safety of Intravitreal Ranibizumab in People With Vision Loss Due to Macular Edema

PHASE3CompletedINTERVENTIONAL
Enrollment

181

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

September 30, 2015

Study Completion Date

September 30, 2015

Conditions
Macular Edema (ME)
Interventions
OTHER

Sham control

The sham vial did not contain active drug (empty sterile vial). The sham injection was an imitation of an intravitreal injection using an injection syringe without a needle touching the eye.

DRUG

Ranibizumab

Ranibizumab 0.5mg/0.5mL was administered intravitreally to the participant.

Trial Locations (61)

1002

Novartis Investigative Site, Riga

1083

Novartis Investigative Site, Budapest

1133

Novartis Investigative Site, Budapest

2000

Novartis Investigative Site, Sydney

2145

Novartis Investigative Site, Westmead

3000

Novartis Investigative Site, Leuven

3010

Novartis Investigative Site, Bern

4012

Novartis Investigative Site, Debrecen

4102

Novartis Investigative Site, Binningen

5000

Novartis Investigative Site, Adelaide

7000

Novartis Investigative Site, Hobart

7249

Novartis Investigative Site, South Launceston

8063

Novartis Investigative Site, Zurich

10122

Novartis Investigative Site, Torino

16132

Novartis Investigative Site, Genova

20123

Novartis Investigative Site, Milan

29010

Novartis Investigative Site, Málaga

31240

Novartis Investigative Site, Saint-Jean

40225

Novartis Investigative Site, Düsseldorf

41380

Novartis Investigative Site, Kocaeli

47011

Novartis Investigative Site, Valladolid

49100

Novartis Investigative Site, Petah Tikva

50134

Novartis Investigative Site, Florence

56124

Novartis Investigative Site, Pisa

69003

Novartis Investigative Site, Lyon

75010

Novartis Investigative Site, Paris

79106

Novartis Investigative Site, Freiburg I. Br

91171

Novartis Investigative Site, Trenčín

93042

Novartis Investigative Site, Regensburg

97517

Novartis Investigative Site, Banská Bystrica

119021

Novartis Investigative Site, Moscow

127486

Novartis Investigative Site, Moscow

168751

Novartis Investigative Site, Singapore

420012

Novartis Investigative Site, Kazan'

4428164

Novartis Investigative Site, Kfar Saba

6423906

Novartis Investigative Site, Tel Aviv

7610001

Novartis Investigative Site, Rehovot

9112001

Novartis Investigative Site, Jerusalem

B3H 2E1

Novartis Investigative Site, Halifax

301 00

Novartis Investigative Site, Pilsen

100 34

Novartis Investigative Site, Prague

F-33076

Novartis Investigative Site, Bordeaux

04103

Novartis Investigative Site, Leipzig

H-6720

Novartis Investigative Site, Szeged

00133

Novartis Investigative Site, Roma

NL-5022GC

Novartis Investigative Site, Tilburg

1105 AZ

Novartis Investigative Site, Amsterdam

602-739

Novartis Investigative Site, Busan

03080

Novartis Investigative Site, Seoul

137-701

Novartis Investigative Site, Seoul

150-034

Novartis Investigative Site, Seoul

08907

Novartis Investigative Site, L'Hospitalet de Llobregat

08190

Novartis Investigative Site, Sant Cugat del Vallès

06100

Novartis Investigative Site, Ankara

GU16 7UJ

Novartis Investigative Site, Frimley

EC1V 2PD

Novartis Investigative Site, London

B18 7QU

Novartis Investigative Site, Birmingham

BS1 2LX

Novartis Investigative Site, Bristol

M13 9WL

Novartis Investigative Site, Manchester

SO16 6YD

Novartis Investigative Site, Southampton

SR2 9HP

Novartis Investigative Site, Sunderland

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY